Searched for
GLP 1 AGONIST
Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like l...- The hidden cost of looking better: What health insurance covers, and what it leaves you to payRising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- Why are Indians suddenly buying more vitamins after starting Ozempic-like weight loss drugs?Demand for vitamin and nutritional supplements is surging in India. This trend follows the increased availability of semaglutide-based weig...
- Eli Lilly’s obesity drug shows up to 30% weight loss in trialEli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This onc...
- No cosmetic job with jabs, warns drug regulator CDSCOThe notice issued by the Central Drugs Standard Control Organisation (CDSCO) cites provisions of the Drugs and Cosmetics Act, 1940, and the...
- Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaDr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- US Stocks | Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats upKailera Therapeutics shares surged 62.5% in their Nasdaq debut after raising $625 million in a U.S. IPO priced at the top end of its range....
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Govt cracks down on GLP-1 drugs: Safety first amid weight-loss hypeIndia's government has released strict rules for GLP-1 drugs, used for diabetes and obesity. These powerful medications are now prescriptio...
- Ahead of its time, a GLP-1 drug almost made it out of IndiaFifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes man...
- Lupin shares in focus after licensing pact with China’s Gan & Lee for GLP-1 drugLupin Ltd has secured exclusive rights in India for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, through a licensing agreement...
- What are GLP-1 medicines? Do they help with weight loss and diabetes, and what are their side effects?GLP-1 medications are prescription treatments used in the UK to manage type 2 diabetes and, in certain cases, medically supervised weight l...
- Pharma major Eli Lilly claims its weight loss drug reduces cardiovascular risks in Type 2 diabetes patientsEli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, reducing mortality a...
- Ozempic injections for weight loss 'could lower cancer risk', researchers sayRecent research suggests that Ozempic and other GLP-1 receptor agonists, commonly used for weight loss, may offer unexpected anti-cancer be...
- Weight-loss drugs: Study involving 2 million people identifies potential benefits beyond obesity treatment and other risksThe study in Nature Medicine explores the potential wider benefits and risks of diabetes drugs GLP-1 receptor agonists. Besides weight loss...
- Mounjaro: Here's all about the wonder antidiabetic medicine touted as the 'most powerful' weight-loss drugMounjaro is making headlines recently. This antidiabetic injectable drug has been touted as the most powerful weight-loss drug available. I...
- Eris enters JV with MJ Pharma to commercialise insulins in domestic marketThe business of the joint venture will be kickstarted with the launch of human insulin in the fourth quarter of FY22.
- New compound may help treat type-2 diabetesThe new technique may enable researchers to quickly find drug candidates that activate cellular receptors in desired ways.
Load More
